Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter study for the long-term follow-up of surviving patients who are
expected to complete or who have completed at least two years of follow-up after treatment
with Iodine I 131 Tositumomab (BEXXAR) on studies CP-97-011, CP-98-025, CP-99-032, or
CP-99-036. All patients will be assessed for survival and disease status, including
subsequent therapy for Diffuse Large B-cell Non-Hodgkin's Lymphoma (NHL), and for long-term
safety. Additionally laboratory evaluations consisting of a thyroid stimulating hormone (TSH)
level and a complete blood cell (CBC) count with a differential and platelet count will be
obtained annually. Additionally, patients who remain in long-term response following Iodine I
131 Tositumomab treatment will be followed for response and progression.